OTCPharm lost its place in the TOP-10 list, and there are now no Russian corporations among the TOP-10 players. Pharmstandard, however, kept its place in the rating despite a small decrease in the share.

 

ТОР25 Corporations on the Russian pharmaceutical market by value share (rubles) in 2014 (Excluding Food Supplements), %

Rating

Corporation

Share

Sales Growth

2014

2013

2014

2013

2014/2013

1

1

Novartis*

5,46

5,79

5

2

2

Sanofi**

5,25

5,53

6

3

3

Bayer Healthcare

3,68

3,74

10

4

5

Takeda

3,12

3,03

15

5

4

Teva

3,07

3,30

4

6

8

Johnson & Johnson

2,93

2,84

15

7

7

Servier

2,91

2,94

11

8

6

Roche

2,82

2,94

7

9

11

Pfizer

2,49

2,16

29

10

9

Berlin-Chemie/Menarini

2,39

2,57

4

11

12

Gedeon Richter

2,15

2,13

13

12

13

Abbott

2,09

2,12

10

13

10

OTCPharm

2,07

2,32

0,1

14

14

Stada

1,95

2,10

4

15

15

Merck Sharp & Dohme

1,88

1,97

7

16

17

KRKA

1,76

1,76

12

17

16

Boehringer Ingelheim

1,71

1,78

8

18

18

GlaxoSmithKline

1,64

1,66

11

19

19

AstraZeneca

1,59

1,56

15

20

20

Astellas Pharma

1,51

1,53

11

21

21

Dr Reddys

1,29

1,30

11

22

22

Pharmstandard

1,28

1,29

11

23

23

Actavis

1,13

0,94

35

24

24

Valenta

1,07

0,92

29

25

25

Reckitt Benckiser

0,88

0,86

14

ТОР25 Total

58,12

59,08

 

 

* Including Sandoz sales
** Including Zentiva sales
Source: IMS Health

TOP-25 corporations account for 58.12% of the market in value, which is slightly less than in 2013. TOP-25 corporations segment grew 10% in 2014, which is 2% below the overall market growth rate of 12%. This can be attributed to increasing value shares of corporations outside the TOP-25 list.

Source: Pharmvestnik